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Staphylococcus aureusA new device for local delivery of antibiotics is presented, with potential use as a drug-eluting fixation pin
for orthopedic applications. The implant consists of a stainless steel hollow tubular reservoir packed with
the desired antibiotic. Release takes place through several orifices previously drilled in the reservoir wall,
a process that does not compromise the mechanical properties required for the implant. Depending on
the antibiotic chosen and the number of orifices, the release profile can be tailored from a rapid release
of the load (ca. 20 h) to a combination of rapid initial release and slower, sustained release for a longer
period of time (ca. 200 h). An excellent bactericidal action is obtained, with 4-log reductions achieved
in as little as 2 h, and total bacterial eradication in 8 h using 6-pinholed implants filled with cefazolin.
 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction Surgical site infection accounts for 15% of all nosocomial infec-Orthopedic medical devices have been extremely successful in
restoring mobility, reducing pain, and improving the quality of life
in millions of individuals each year [1]. Despite the advances
achieved in orthopedic surgery, sterility levels in operating rooms,
and developments in parenteral antibiotic prophylaxis, bacterial
infections, mostly caused by Staphylococcus aureus and Staphylo-
coccus epidermidis, continue to be a major complication after surgi-
cal procedures [2]. Unfortunately, most strains of those bacteria
have the ability to form biofilms on medical devices becoming a
major cause of refractory biofilm-associated infections. The biofilm
bacteria show phenotypic resistance to antibiotics [3] and can fre-
quently give rise to serious infections leading to prolonged hospi-
talization, complex revision procedures, and sometimes complete
failure of the implant, requiring secondary surgery for its removal,
increasing the economic burden and mortality rate [4].tions and, among surgical patients, represents the most common
nosocomial infection [5]. Most surgical site infections are believed
to be acquired during surgery [6] being a 6-h post-implantation the
‘‘decisive period” identified during which prevention of bacterial
adhesion is critical to achieve a long term success of an implant
[7]. Over this period, an implant is particularly susceptible to sur-
face colonization. At extended periods, certain strains of adhered
bacteria are capable of forming biofilm at the implant–tissue inter-
face. The formation of biofilm requires the initial adhesion of bac-
teria to an implant surface and therefore, inhibiting bacterial
adhesion is often regarded as the most critical step to prevent
implant-associated infections [8]. Usually those early infections
in orthopedic implants are caused by aggressive bacteria, such as
S. aureus and gram-negative bacilli and acquired during the surgi-
cal procedure whereas delayed infections are mostly caused by
hematogenously spread bacteria [9].
Almost all implants can be colonized by bacteria including coro-
nary and biliary stents, vascular access devices, catheters, pace-
makers, valves, cochlear implants, prosthetic joints, orthopedic
fixation devices, breast implants and contact lenses [10]. Besides
preventive measures [11], current investigation is focused on
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adherent surfaces to prevent them from fouling by adhesins such
as polysaccharides and other components of bacterial membranes
such as teichoic acids in gram-positive bacteria [12]. However, pre-
venting bacterial proliferation and biofilm formation by manipu-
lating the physicochemical surface characteristics is a challenging
task.
Koseki et al. [13] have recently shown how different solid
orthopedic implant materials (Co–Cr–Mo, Ti–6Al–4V, pure tita-
nium and stainless steel) are rapidly colonized by bacteria and
the biofilms formed on those surfaces show the same coverage rate
after 2–4 h of incubation in vitro independently of the nature of the
implant. A number of investigations have been focused on passive
coatings (e.g. crystalline anatase-TiO2, hydrophilic polymethacrylic
acid, polyethylene oxide and protein resistant polyethylene glycol)
[14–17] that modify the physiochemical surface properties of the
implant to create anti-adhesive surfaces for bacteria. Their effi-
ciency seems to be limited and depends on the bacterial species
concerned [8]. Other promising alternatives include micro or
nano-structuration of the surface [18] with the aim of mimicking
nature surfaces that are less prone to bacterial adhesion (i.e., drag-
onfly wings, lotus leaves).
On the other hand, the use of standard medical protocols such
as conventional systemic delivery of antibiotics for both preven-
tion (prophylaxis) and treatment suffers from the drawbacks of
systemic toxicity with associated renal and liver complications,
poor penetration into ischemic and necrotic tissue that are typical
findings on post-traumatic and postoperative tissue, and need for
hospitalized monitoring [19,20]. Clearly, a more efficient way of
delivering antibiotics is desirable, and this has given rise to a vari-
ety of in situ eluting devices.
The main advantage of in situ release is that it allows therapeu-
tic dosages to be delivered at or near target locations, maximizing
efficiency while minimizing systemic side effects. To achieve this,
antibiotic molecules could be integrated within the device: mixed
with the bone cement, adsorbed on porous structures, loaded in
internal cavities or deposited on its external surface [21].
Antibiotic-doped bone cements (e.g., polymethylmethacrylate –
PMMA, acrylic cement) remains a widely used material in orthope-
dic surgery and is effective on reducing the risk of infection [22].
However, the occurrence of infected implants is still a major con-
cern and several important disadvantages persist. These include
the induction of antibiotic resistance mainly caused by the pro-
longed and irregular release of antibiotic, and the fact that despite
the aim of achieving early and complete release, a large proportion
of the drug is not released: in vitro studies show that only 5–8% of
the added antibiotic is released [23–25]. Finally, there is the prob-
lem of achieving the desired release rate in a reproducible way. In
an ideal system, the elution rate would mainly depend on the
surface area and porosity of the cement, parameters that can be
controlled in the production process. However, real system rates
are difficult to control and reproduce, because the antibiotic dif-
fuses predominantly through the defects or cracks that are formed
during the irregular cement drying process.
Permanent or long-duration metal implants offer additional
opportunities to introduce drug delivery capabilities and have been
the subject of intense investigation during the past decade [26].
Porous metals such as macroporous stainless steel [27,28] and
macroporous titanium [29] were studied in vitro and in vivo show-
ing clear advantages as the implant can provide both mechanical
support and controlled local drug delivery at target tissues. In this
regard, Park et al. [30] demonstrated that a hollow titanium
implant perforated with microholes and loaded with a
dexamethasone-based cartridge was able to provide a sustained
release of this anti-inflammatory drug up to 7 weeks after
implantation.In this work, we study drug release from a new pre-filled stain-
less steel hollow tubular reservoir and we demonstrate the in vitro
biocidal action of the encapsulated drug from the device. This sys-
tem is presented as a model delivery device for antibiotics, with
potential use in drug-eluting fixation pins for orthopedic applica-
tions. About 5% of internal fixation devices become infected, being
the incidence of infection after internal fixation of 0.5–2% and up to
30%, for closed and open fractures, respectively [31]. These infec-
tions could be fought locally by antibiotic-filled hollow fixation
pins, in which part of the length has been made capable of drug
release. As a proof of concept, we designed four different tubular
reservoirs made of hollow 316L stainless steel implants filled with
antibiotic in which a variable number of through pinholes (2, 4, 6
and 8 equidistant orifices) act as gates that control the drug diffu-
sion kinetics. The rate of drug release would then be governed by
molecular diffusion through the pinholes, a process that depends
on drug solubility, concentration difference between the inside
and outside of the reservoir and the number and size of the orifices.
In this way, uncontrollable factors (e.g. the number and size of
cracks formed during the bone cement drying process,) are largely
avoided, and a more robust control on the release rate can be
obtained. Depending on the medical procedure requirements,
release rates can be tailored by selecting drugs with the appropri-
ate solubility in physiological media and by adjusting the number
and diameter of pinholes in the implant. This model is especially
relevant for clinical application in trauma because some of the cur-
rently used devices could be easily re-designed as partially hollow,
drug-eluting structures without compromising their mechanical
properties.
2. Material and methods
Hollow 316L stainless steel medical grade tubes were mecha-
nized to enable their use as drug storage reservoirs and delivery
implants with one open end (used to load the corresponding
antibiotic) and a blind end welded on the opposite side. After load-
ing the open end was closed with the aid of a screw PTFE cap. Four
different models of implants were designed with a variable num-
ber of through pinholes (2, 4, 6 and 8 equidistant orifices), each
with a diameter of 500 lm. Each implant is 2.5 cm long and
0.6 cm O.D. having a wall thickness of 1.6 mm (Fig. 1). The design
of these implants allows a controlled diffusion of the desired drug
from the inner space, through a posterior permeation across the
corresponding orifices and then to the exterior space. For the
experiments in this work, the antibiotics were loaded as a dry
solid. This means that liquid from the outside had to enter the
reservoir to dissolve the antibiotic before the dissolved molecules
could diffuse out. In this work, the inner volume of the hollow
implant (129 mm3 when the lid on) was carefully loaded with
either 100 mg of lyophilized commercial linezolid (Zyvox, Pfizer,
NY, USA) or 100 mg of commercial cefazolin powder (Cefazolina
Normon, Madrid, Spain). According to the manufacturer, each
ml of the pharmacological solution of Zyvox contains 2 mg of
linezolid, 45.7 mg of glucose and 0.38 mg of sodium (as sodium
hydroxide). The solution also contains sodium citrate, citric acid
anhydrous, hydrochloric acid and water for injections. On the other
hand, 1 g of powder Cefazolina Normon contains 1 g of sodic cefa-
zolin. Water solubilities for sodium cefazolin and Zyvox are 50
and 3 mg/ml, respectively.
2.1. Kinetic studies of antibiotics release
Solubility and diffusion rate were evaluated by immersing the
linezolid or cefazolin loaded implants in 200 ml of simulated body
fluid (SBF) at 37 C under stirring (30 rpm). SBF was prepared
according to the method described by Kokubo et al. [32] having
Fig. 1. (A) Lateral image of the four different models of implants tested. Note the equidistant through pinholes. (B) X-ray microtomography of one of the implants (6 pinholes)
to show the hollow interior and the screw-in PTFE cap. Note the equidistant through pinholes.
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148.8Cl:4.2HCO3:1HPO42. The implants were suspended to per-
mit complete contact with the SBF. The linezolid and cefazolin
release rates were evaluated in triplicate on independent experi-
ments by measuring the drug concentration in SBF by using
251 nm (linezolid) or 270 nm (cefazolin) UV–vis spectrophotome-
try at fixed time intervals. Several antibiotic solutions at concen-
trations of 0, 0.01, 0.025, 0.05, 0.1, 0.2, 0.25, 0.5, 0.75 and 1 mg/
ml were used as calibration standards. The means, standard devia-
tions and reproducibility were calculated. The reproducibility can
be defined as the closeness of the agreement between independent
results obtained with the same method on the test material but
under different conditions, in this case, at different experiments.
It was measured by using the intra-class correlation coefficient
(ICC) for a 95% confidence interval.2.2. Mechanical studies of the implants
The objective of the mechanical tests is firstly to check the
effect of the presence of the pinholes on the global strength of
the device, and secondly to compare the load level supported
by the device with physiological loads achievable on human
bones.
Standardized tests were performed on the implants to analyze
the possible influence of the pinholes on the global mechanical
strength of the delivery device. Two groups of implant models
were examined: the first one without any pinhole and the second
one with six pinholes. The geometrical dimensions of all the exam-
ined implants were the same, as described in former section,
except for the presence of the pinholes. Compression and bending
represent the two main load states appearing in long bones as the
case of the limbs during the normal activity of the patient.
Therefore uniaxial compression and three point bending mechani-
cal tests were performed in a universal hydraulic testing machine
Instron 8874. This machine has a resolution of 1 N for a 25 kN load
cell and a displacement control test was applied at an axial velocity
of 0.1 mm/s.
Implants were subjected to unconfined compression uniaxial
tests, positioning the samples between two steel disks and allow-
ing a lateral displacement of the upper end. Five valid tests were
carried out for each group, without and with six pinholes. The axialstress-axial strain curves for the groups with and without pinholes
were compared.
For the three point bending tests the group of samples with pin-
holes was divided in two subgroups depending on the relative
position of the perforations. Three samples were placed with the
holes oriented in the direction of the load while for other three
implants the holes were set up in a perpendicular direction. There-
fore a total of six valid tests were performed for pinholed implants
and other six for intact devices. Displacement control tests at a
0.1 mm/s central point velocity were carried out in an Instron
8874 testing machine with a 25 kN load cell. The tests finished
when the total collapse of the samples was reached. Central point
force–displacement curves between different groups were ana-
lyzed. We tested 6-pinholed samples because they represent the
worse situation from a mechanical point of view, because the
applied force, and consequently the maximal bending moment,
coincides with the central holes of the sample. For the other sam-
ples the maximal bending moment does not sit on any of the holes.
2.3. Bacterial challenge studies
S. aureus strain ATCC 6538 was used in all the experiments. Four
and six pinholed implants were selected for the bacterial challenge
based on the results obtained previously in antibiotic release
experiments (see results below).
The classical broth microdilution method [33] was applied to
determine the minimal inhibitory concentration (MIC) and the
minimal bactericidal concentration (MBC). Previously to the assay,
each empty implant was autoclave sterilized, and then filled with
lyophilized commercial linezolid or commercial cefazolin powder,
according to each experiment. A positive control experiment was
included using a pin with no antibiotic. Subsequently they were
placed in tubes containing 10 ml of TSB and 10 ll of a stationary
culture (109 CFU/ml) of the isolate, resulting in a co-culture in
exponential growth phase S. aureus colonies (106 CFU/ml) and
maintained at 37 C. A tube with an empty implant and TSB with-
out bacteria was used as negative control, to check the sterility of
the implants.
The bacterial growth on the media was studied at 2, 8, 24 and
48 h. The average number of bacteria was measured by TSA plate
count. The experiments were independently done in triplicate
and means and standard deviations were calculated.
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3.1. Kinetic studies of antibiotics release
The release curves of linezolid and cefazolin from the different
loaded implants in SBF are shown in Fig. 2. All experiments were
performed in triplicate and results are presented as mean ± stan-
dard deviation.
For implants with four holes and above, all profiles exhibited a
first burst release phase followed by a relatively slower release.
The burst release phase is more marked for cefazolin, which has
a much larger solubility. The total amount released during this first
phase differs for each implant. The release profiles of four, six and
eight pinholed implants were markedly faster for cefazolin, espe-
cially after the initial burst release. However, similar release pro-
files are obtained for both cefazolin and linezolid when only two
pinholes were used in the implant.3.2. Mechanical studies of the stainless steel implants
The axial stress–strain curves for the unconfined compression
tests are presented in Fig. 3. The initial part of the curves repre-
sents the elastic behavior of the implants, exhibiting the same elas-
tic response for both groups. The top end of the samples allowed a
lateral displacement, therefore the mechanical failure of the
implant would be caused by a combination of plastic behavior
and buckling, conducing to some variations of maximal axial stress
depending on whether plasticity or buckling prevailed. The maxi-
mal stress range obtained for intact implants was 650–850 MPa
and for holed samples 750–850 MPa.
Fig. 4 represents the force–displacement curves of the central
point of the samples subjected to the three point bending experi-
ment. In this case, the repeatability of the tests is much higher thanFig. 2. Linezolid and cefazolin released as a percentage of the antibiotic initially loaded
profile obtained without replenishing with fresh immersion media. Reproducibility: 2 pin
0.99) for linezolid and cefazolin, respectively.in the compressive experiments, especially for intact samples. The
curves show a first zone of elastic behavior until a load of about
4000 N was reached indicating the plasticity of external points of
the central section of the tube. The second zone corresponds to
an elastoplastic response with the propagation of plasticity in the
points of the central section of the sample. Intact and transversally
oriented holed samples present an analogous response, while for
samples with the holes oriented in the load direction a different
behavior can be observed from a load about 6500 N upward.3.3. Bacterial challenge studies
The MIC and MBC for the linezolid and cefazolin were sepa-
rately determined. For linezolid the resulting values were 2 and
16 lg/ml and for cefazolin 1.56 and 12 lg/ml, respectively. These
results are in agreement with values previously reported by other
authors [34–36].
Both loaded implants showed a strong bactericidal effect after
short exposure times (complete bacterial eradication after 24 and
8 h for linezolid and cefazolin-loaded implants, respectively,
Fig. 5). The control implant exhibited a linear bacterial growth
for linezolid and cefazolin experiments, reaching values around
1010 CFU/ml after 48 h of incubation.
After only 2 h of contact, six pinholed cefazolin-loaded implants
showed the fastest bactericidal effect presenting 6.6  103 CFU/ml
whereas four pinholed implants showed 3.6  105 CFU/ml and
control implant reached 3.3  107 CFU/ml, a 4 log increase com-
pared to the six pinholed cefazolin-loaded implant at the same
experimental time. For linezolid, the effect seemed to be somewhat
slower: four and six pinholed linezolid-loaded implants showed a
similar count around 105 CFU/ml at 2 h, one order of magnitude
lower than the control implant (2.1  106 CFU/ml). At 8 h, the con-
trol implant reached 9.86  108 CFU/ml while 6 pinholed implantsin the different implants immersed in 200 ml of simulated body fluid (SBF). Release
holes (0.95; 0.99); 4 pinholes (0.88; 0.99); 6 pinholes (0.88; 0.98); 8 pinholes (0.84;
Fig. 3. Axial stress–strain curves for the compression test. (A) No pinholed samples (blank). (B) Six pinholed samples.
Fig. 4. Central point force–displacement for the three point bending test. (A) No pinholed samples. (B) Six pinholed samples oriented in load and transversal directions.
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count) and four pinholed implants showed 3.46  105 CFU/ml. A
marked difference in terms of turbidity (caused by bacterial
growth) is evident between linezolid and cefazolin eluting
implants and the control experiments without any antibiotic at
48 h (Fig. 6).
4. Discussion
Several types of percutaneous and internal metallic devices are
used routinely in traumatology and orthopedic surgery to repair,
fix or reconstruct damaged bones. The engineering of orthopedic
implants that can both prevent infection and facilitate the healing
of injured bones could serve as a useful tool in this area by provid-
ing the required mechanical strength while offering local antibiotic
administration. In addition, with an adequate design of the
implant, release at the desired rate would occur without any addi-
tional action, avoiding any patient compliance issues.
The 316L stainless steel used on this proof of concept is a widely
applied material for biomedical implants. We propose a new
design for these bone fixation devices with incorporated antibiotic
controlled-release functionality, in which different release profiles
can be obtained by changing the type of antibiotic and the number
or size of orifices. For the experiments in this work, the antibiotics
were loaded as a dry solid. Alternatively, loading the pins with a
paste containing a partially pre-dissolved mixture can also be con-
templated. In this way, the preventive action can be tailored,
according to the patient and medical procedure needs.
The release profiles obtained in this work present a good repro-
ducibility, as shown by the relatively small deviations in triplicate
experiments, especially in the case of cefazolin. However, there are
marked differences in the observed behavior depending on the
number of pinholes (two or more than two pinholes) and on the
type of antibiotic. Thus, all implants with four pinholes or more
exhibited an initial burst release followed by a slower release
phase. However with two pinholes, the process is different, and
an induction period appears in the graph, with upward convexityobserved for a few hours in the curves of both antibiotics. Also,
the release rates are much faster for cefazolin in all implants with
four or more pinholes, while they are comparable in implants with
only two pinholes. These observations can be explained by consid-
ering that the antibiotic release process possibly takes place
through the following steps: (i) Surrounding liquid enters the
implant; (ii) antibiotic dissolution takes place; (iii) antibiotic is
released through the pinholes.
When there is enough exchange area (4 pinholes or more), the
surrounding liquid enters the implant rapidly, and dissolution of
the antibiotic gives rise to a near-saturated liquid solution close
to the inner side of the wall. This creates a gradient for diffusion
and release of the antibiotic starts immediately: the antibiotic
located closer to the orifices rapidly dissolves, giving rise to the
observed burst release for both antibiotics. Since the saturation
concentration of cefazolin is one order of magnitude higher than
that of linezolid (cefazolin and linezolid solubilities in water at
20 C are 50 and 3 mg/ml, respectively) [37,38] the driving force
for release is much higher, and thus both the magnitude of the
burst release stage and the overall release rate through the process
are considerably higher for cefazolin, as can be seen for all exper-
iments with 4 or more orifices in Fig. 2. As time progresses, the dis-
solution front moves inward in the implant and the outside
concentration also increases. Both aspects combine to decrease
the concentration driving force and as a consequence the system
enters in a phase of decreasing antibiotic release rates until all
the antibiotic is eventually released (a process that takes 20–40 h
for cefazolin, depending on the number of pinholes in the implant
and well over 100 h for linezolid). In contrast, when there are only
two pinholes, the amount of liquid penetrating the implant is
strongly reduced, and capillary processes dominate initially, taking
liquid away from the orifices (which gives rise to the observed
induction period), and slowing down the release process, as shown
in Fig. 2 where comparable rates are obtained for both antibiotics.
A release profile with a burst phase followed by a sustained
release of the antibiotic is highly desirable for applications like
fracture fixation, where a fast initial release is needed in order to
Fig. 5. Kinetics of the bactericidal action for four and six pinholed implants in a 48 h experiment.
Fig. 6. Digital photograph of four and six pinholed implants containing cefazolin (A) and linezolid (B) and without antibiotics (C) after 24 h culturing with S. aureus. Note the
marked difference in the turbidity of the media.
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before they adhere and create a biofilm; this is important because
the biofilm formed protects the bacteria from the immune system
and hinders penetration of antibiotics [39]. The process of biofilm
formation is generally thought to be a two-step model. First, bacte-
ria rapidly adhere to the biomaterial surface by means of
hydrophobic and electrostatic interactions. Then the bacteria pro-
liferate and accumulate to form multilayered cell clusters on thesurface through molecular and cellular interactions, producing
the biofilm [40]. The prevention of the initial adhesion of bacteria
to an implant surface is the most important step to avoid biofilm
formation. Our results indicate that it is desirable having at least
four orifices in the implant (possibly six, if a higher initial flux is
required), to ensure a sufficient influx of liquid and fast initial
antibiotic release. It is important to point out that no leftover drugs
were observed inside the hollow interior after the drug diffusion
270 M. Gimeno et al. / European Journal of Pharmaceutics and Biopharmaceutics 96 (2015) 264–271tests. This is of the utmost importance to avoid any potential bac-
terial resistance to the selected antibiotic.
After the surrounding biological fluid has entered the implant
and dissolved part of the packed antibiotic, two parameters control
the release rate: the total area available for release, which is given
by the number of pinholes (and their size, although this aspect has
not been investigated in this work), and the solubility of the antibi-
otic, which gives the maximum concentration attainable in the
inner fluid. A higher water solubility and reduced particle size of
the cefazolin (<100 lm) compared to linezolid (<300 lm) (see
Supplementary information) favor a faster drug release. A higher
porosity was expected for the linezolid-based packed beds, due
to its larger particle size (in packed beds the size of the interparti-
cle spaces is usually similar to the particle size). However, it is rea-
sonable to postulate that drug solubility plays a controlling role
rather than interparticle diffusion limitations.
Mechanical tests were performed to check the effect of the pres-
ence of the pinholes on the strength of the device and to compare
the load level supported by the device. It can be concluded that the
presence of the six holes with the characteristics described does
not modify the compressive response of the implant under the
loads tested. This level of maximum stress borne by the devices
is much higher that the ultimate compressive strength reported
for human cortical bone 170 MPa [41]. The three point bending
experiment showed that intact and transversally oriented holed
samples present an analogous response, while for samples with
the holes oriented in the load direction a different behavior can
be observed from a load about 6500 N upward. The reason for such
load reduction is that the central orifice coincides with the section
just above the applied load, reducing the resistant inertia moment
and contributing to a stress concentration around the hole.
Nevertheless the maximum bearing load is still well above the
maximum physiological load supported over a limb, 2.5 times body
weight [42]. Therefore neither transversal nor vertical oriented
holes are expected to have an impact on the flexural strength of
the device under conceivable application scenarios.
Our results indicate that, for both antibiotics tested, an excel-
lent bactericidal action is possible when using drug eluting
implants with a sufficient number of orifices. Thus, after only 2 h
of contact, cefazolin-loaded implants with 6 pinholes achieved a
4-log reduction in bacterial count. With linezolid the 4-log reduc-
tion was achieved after 8 h, but antibiotic release was extended for
a much longer period of time. At 2 h cefazolin implants had
released approximately 7% and 45% of their load when using four
and six pinholes, respectively. This compares with linezolid-
loaded implants that after 8 h had released approximately 4%
and 10% of their load when using four and six pinholes, respec-
tively. There was a complete bactericidal effect at 24 h and 8 h
for linezolid and cefazolin-loaded implants, respectively. This is
related not only to the faster release rate of cefazolin due to its
higher solubility but also to the fact that the commercial linezolid
used contains other components on its pharmaceutical formula-
tion in addition to the antibiotic.5. Conclusions
Despite the range of prophylactic methods available, bacterial
infection remains a major problem in orthopedic procedures. In
this context, on-site delivery of antibiotics offers a powerful alter-
native to fight implant colonization by bacteria in the initial period
after intervention. In the absence of a more detailed assessment,
the combination of a fast initial delivery followed by prolonged
release at a lower rate from a local antibiotic-eluting device
appears as a suitable release profile for both traumatology and
orthopedic surgery.As a proof-of-concept we have presented a simple device that
allows localized delivery of therapeutic compounds. We have
shown that release profiles can be adjusted by selecting the num-
ber of release orifices and the type of antibiotic and its solubility.
With the number of perforations used in this work, an excellent
bactericidal action can be obtained. The release rates can be tai-
lored to match the patient’s needs without compromising the
mechanical properties of the implant.
This work presents the device concept and preliminary in vitro
results that show how the release profile can be tailored. Its clinical
application would involve re-designing some of the implants cur-
rently in use as partially hollow, drug eluting structures. In vivo
studies are necessary to corroborate the efficacy of the system
when facing a more complex scenario with other factors such as
body fluid dynamics, clearance and inflammation involved in the
healing processes.
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